AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05390190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non ablative radiofrequency
Description: Device
Study NCT04949971 — intervention group
Intervention type: BEHAVIORAL
Intervention: High volume group
Description: Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
Study NCT05696782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
Study NCT05696782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
Description: Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
Study NCT05696782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Description: Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
Study NCT05696782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council (mMRC) dyspnea scale
Description: Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
Study NCT04966585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Delayed Release Oral Tablet
Description: Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Study NCT04966585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablet
Description: Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Study NCT06560307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study NCT06560307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study NCT06026696 — intervention group
Intervention type: OTHER
Intervention: follow-up
Description: Long term follow-up
Study NCT06240208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
Study NCT04841915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Protein Diet
Description: Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
Study NCT06004674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox 40mg
Description: Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
Study NCT05912166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wakeful Spanish
Description: Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content.
Study NCT04767646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation program with CPNB
Description: The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program
Study NCT06255340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185
Study NCT06255340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3031185
Description: Placebo
Study NCT04841915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical dietician
Description: Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
Study NCT04841915 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical dietician
Description: Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
Study NCT04228003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pendulum Glucose Control formulation for T2D
Description: All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃.
Study NCT04743063 — intervention group
Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
Study NCT04743063 — intervention group
Intervention type: DRUG
Intervention: Angiotensin II Receptor Blockers
Description: Initiation of ARBs, identified using prescription fill in pharmacy claims
Study NCT04841915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: 4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
Study NCT04841915 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: 4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
Study NCT04849325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Description: Subjects in this arm will be treated with IBS Titan™.
Study NCT04849325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) Device
Description: Subjects in this arm will be treated with PTA device.
Study NCT05333783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Exposure Therapy Based on ExposXR software
Description: The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
Study NCT05730478 — intervention group
Intervention type: DEVICE
Intervention: ASOCT&UBM
Description: glaucoma assesment by ASOCT \&UBM
Study NCT05730478 — intervention group
Intervention type: DRUG
Intervention: Glaucoma therapy
Description: ASOCT and UBM parameters Comparison
Study NCT05730478 — intervention group
Intervention type: DRUG
Intervention: Glaucoma therapy
Description: Comparison
Study NCT04652765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camostat Mesilate
Description: Camostat 600mg by mouth four times a day, for a total of 7 days
Study NCT04652765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 150 mg
Description: Bicalutamide 150mg by mouth once daily, for a total of 7 days
Study NCT05148663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCM Hemorrhagic Panel
Description: Biomarker
Study NCT06608732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inaticabtagene autoleucel
Description: CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
Study NCT06606600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Kebbi robot interventions
Description: The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
Study NCT06663969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal Interference
Description: Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
Study NCT06606158 — intervention group
Intervention type: OTHER
Intervention: Exercises program
Description: Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.
Study NCT06606158 — intervention group
Intervention type: OTHER
Intervention: App exercises program
Description: A strength, mobility, and balance exercise program delivered through a mobile app.
Study NCT05700422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Nasal Spray
Description: OC-01 (varenicline solution) 0.03 mg nasal spray
Study NCT06314152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight mesh fixation in 3 points or 1 point
Description: Lightweight mesh fixation in 3 points
Study NCT06314152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lightweight mesh fixation in 3 points or 1 point
Description: Lightweight mesh fixation in 3 points
Study NCT06674759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongren-Dahuoluo Bolus
Description: 0.72g,2 times a day, oral, for 24 weeks.
Study NCT06674759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tongren-Dahuoluo Bolus Placebo
Description: 0.72g,2 times a day, oral, for 12 weeks.
Study NCT06679504 — intervention group
Intervention type: PROCEDURE
Intervention: Fibrin glue fixation
Description: Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation
Study NCT06679504 — intervention group
Intervention type: PROCEDURE
Intervention: Tack fixation
Description: Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
Study NCT06674876 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blog writing
Description: Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
Study NCT05369260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based cervical and scapular stabilization exercises
Description: Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
Study NCT06675708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups
Study NCT06675708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
Study NCT06675877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality camera
Description: The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
Study NCT06675448 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: Participants will undergo the Mitraclip procedure according to current standards of practice
Study NCT06675448 — intervention group
Intervention type: OTHER
Intervention: Moderate MR
Description: Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
Study NCT06674369 — intervention group
Intervention type: DEVICE
Intervention: Peli prism for hemianopia
Description: Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
Study NCT06675214 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose IMRT
Description: GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy
Study NCT06675214 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gradient Fractionated IMRT
Description: GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study NCT06675214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study NCT06679907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLinQ® device
Description: The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.
Study NCT06679907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipsys® device
Description: The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
Study NCT05369260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based cervical and core stabilization exercises
Description: Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
Study NCT06679907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No device
Description: Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
Study NCT06231836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNO)
Description: O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
Study NCT06690216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT （[18F]AlF-NOTA-PCP2）
Description: This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
Study NCT06690216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
Description: This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
Study NCT06690853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Coordinative training
Description: The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.
Study NCT06690853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training (control group)
Description: The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
Study NCT06231836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula
Description: O2 is administered by nasal cannula at 6L/min
Study NCT06690580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based on the knowledge motivation behavior skills model
Description: Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
Study NCT06688565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hativ® electrocardiogram monitoring
Description: Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis